Marina Biotech (MRNA) Given “Buy” Rating at JPMorgan Chase & Co.

Share on StockTwits

JPMorgan Chase & Co. reaffirmed their buy rating on shares of Marina Biotech (OTCMKTS:MRNA) in a report published on Thursday morning.

Several other research analysts have also weighed in on the stock. Goldman Sachs Group started coverage on shares of Marina Biotech in a report on Wednesday, January 2nd. They set a buy rating and a $25.00 price objective on the stock. Needham & Company LLC started coverage on Marina Biotech in a research note on Wednesday, January 2nd. They issued a buy rating and a $28.00 target price on the stock. Piper Jaffray Companies initiated coverage on Marina Biotech in a report on Wednesday, January 2nd. They set an overweight rating and a $24.00 target price on the stock. Bank of America initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They issued a buy rating and a $20.00 price target on the stock. Finally, Morgan Stanley initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They issued an overweight rating and a $29.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $24.38.

Shares of OTCMKTS:MRNA traded up $0.52 on Thursday, reaching $17.00. 580,408 shares of the company were exchanged, compared to its average volume of 1,530,243. Marina Biotech has a 1-year low of $13.03 and a 1-year high of $22.75.

Marina Biotech Company Profile

Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.

Recommended Story: S&P 500 Index

Analyst Recommendations for Marina Biotech (OTCMKTS:MRNA)

Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply